DermTech, Inc. announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3661 USD | -12.83% | -35.78% | -79.08% |
May. 14 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
Apr. 22 | North American Morning Briefing : Stock Futures -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-79.08% | 14.54M | |
-5.86% | 12.09B | |
-4.87% | 8.21B | |
+5.47% | 5.74B | |
+27.42% | 5.64B | |
-9.89% | 4.16B | |
-58.99% | 2.88B | |
+8.97% | 2.69B | |
-5.19% | 2.33B | |
+21.58% | 2.17B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Announces Contract with Hawaii Blues Plan for the Foundational Assay of Its Dermtech Melanoma Test